972 similar documents, closest first
- US 12,291,709 B2Granted 6 May 2025Compositions and methods for modulating apolipoprotein (a) expression
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting
Ionis Pharmaceuticals, Inc.
- US 12,410,430 B2Granted 9 Sep 2025Modulating apolipoprotein (A) expression
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting
Ionis Pharmaceuticals, Inc.
- US 10,557,137 B2Granted 11 Feb 2020Modulating apolipoprotein (a) expression
1. A method of treating a disease or condition in a human comprising administering to the human 75 mg to 85 mg of an oligomeric compound having the
Ionis Pharmaceuticals, Inc.
- US 11,299,736 B1Granted 12 Apr 2022Conjugated antisense compounds and their use
1. A compound comprising a conjugate having the formula
Ionis Pharmaceuticals, Inc.
- US 7,038,037 B2Granted 2 May 2006Method for sequential support-bound synthesis of conjugated oligomeric compounds
1. A method of preparing a conjugated oligomeric compound comprising the steps of: providing a bridging unit bound to a support medium, said bridging
Isis Pharmaceuticals, Inc.
- US 9,181,549 B2Granted 10 Nov 2015Conjugated antisense compounds and their use
1. A compound having the formula (XXVI): wherein: T2 is a group comprising a conjugate linker, a cleavable moiety, and an oligomeric compound
Isis Pharmaceuticals, Inc.
- US 2017/0145424 A1Published 25 May 2017Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
1. A composition for non-parenteral administration comprising: a conjugated oligomeric compound having a conjugate group comprising from 1 to 3
Ionis Pharmaceuticals, Inc.
- US 6,878,805 B2Granted 12 Apr 2005Peptide-conjugated oligomeric compounds
1. An oligomeric compound having formula I: wherein: one of T1, T2, and T3 is L—R2; another of T1, T2, and T3 is hydrogen, hydroxyl or a protected
Isis Pharmaceuticals, Inc.